术前力量、辅助行走、起身、爬楼梯和跌倒(SARC-F)评分可预测结直肠癌患者是否需要停止辅助化疗。

IF 1.9 3区 医学 Q3 ONCOLOGY
Dain Shin, Nak Hoon Son, Woon Kyung Jeong, Seong Kyu Baek, Sung Uk Bae
{"title":"术前力量、辅助行走、起身、爬楼梯和跌倒(SARC-F)评分可预测结直肠癌患者是否需要停止辅助化疗。","authors":"Dain Shin, Nak Hoon Son, Woon Kyung Jeong, Seong Kyu Baek, Sung Uk Bae","doi":"10.1002/jso.70097","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>Sarcopenia adversely affects clinical outcomes in patients with cancer. Studies indicate that sarcopenia significantly predicts chemotherapy-induced dose-limiting toxicities, including early discontinuation, delay, and dose-reduction, in patients with colorectal, esophageal, digestive, hepatocellular, and renal cancers. The Strength, Assistance for walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire is a simple and effective tool for sarcopenia screening. Adjuvant chemotherapy is the standard treatment for advanced (Stages II/III) colorectal cancer (CRC). Predicting chemotherapy discontinuation could help improve oncologic outcomes. This study aimed to evaluate the correlation between the SARC-F score and chemotherapy discontinuation.</p><p><strong>Methods: </strong>This study included 139 patients with CRC who underwent surgery between July 2016 and June 2023, received adjuvant chemotherapy and completed the SARC-F questionnaire before surgery. The SARC-F includes five items, each scored from 0 to 2. Patients were divided into two groups based on optimal SARC-F cutoff value. Treatment discontinuation was analyzed using a logistic regression model.</p><p><strong>Results: </strong>Patients were categorized into high-SARC-F (n = 18) and low-SARC-F (n = 121) groups. Patients in the high-SARC-F group were older (p < 0.001), had higher rates of hypertension (p = 0.001) and diabetes mellitus (p = 0.017), elevated preoperative C-reactive protein levels (p < 0.001), and a higher incidence of treatment discontinuation (p = 0.010). Univariate and multivariate analyses identified a high SARC-F score as an independent risk factor for chemotherapy discontinuation (odds ratio 3.905, 95% confidence interval 1.100-13.867).</p><p><strong>Conclusions: </strong>Our findings indicate that the SARC-F score reflects sarcopenia characteristics and can predict adjuvant chemotherapy discontinuation in patients with CRC.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preoperative Strength, Assistance in Walking, Rising From a Chair, Climbing Stairs, and Falls (SARC-F) Score Predicts Adjuvant Chemotherapy Discontinuation in Patients With Colorectal Cancer.\",\"authors\":\"Dain Shin, Nak Hoon Son, Woon Kyung Jeong, Seong Kyu Baek, Sung Uk Bae\",\"doi\":\"10.1002/jso.70097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objectives: </strong>Sarcopenia adversely affects clinical outcomes in patients with cancer. Studies indicate that sarcopenia significantly predicts chemotherapy-induced dose-limiting toxicities, including early discontinuation, delay, and dose-reduction, in patients with colorectal, esophageal, digestive, hepatocellular, and renal cancers. The Strength, Assistance for walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire is a simple and effective tool for sarcopenia screening. Adjuvant chemotherapy is the standard treatment for advanced (Stages II/III) colorectal cancer (CRC). Predicting chemotherapy discontinuation could help improve oncologic outcomes. This study aimed to evaluate the correlation between the SARC-F score and chemotherapy discontinuation.</p><p><strong>Methods: </strong>This study included 139 patients with CRC who underwent surgery between July 2016 and June 2023, received adjuvant chemotherapy and completed the SARC-F questionnaire before surgery. The SARC-F includes five items, each scored from 0 to 2. Patients were divided into two groups based on optimal SARC-F cutoff value. Treatment discontinuation was analyzed using a logistic regression model.</p><p><strong>Results: </strong>Patients were categorized into high-SARC-F (n = 18) and low-SARC-F (n = 121) groups. Patients in the high-SARC-F group were older (p < 0.001), had higher rates of hypertension (p = 0.001) and diabetes mellitus (p = 0.017), elevated preoperative C-reactive protein levels (p < 0.001), and a higher incidence of treatment discontinuation (p = 0.010). Univariate and multivariate analyses identified a high SARC-F score as an independent risk factor for chemotherapy discontinuation (odds ratio 3.905, 95% confidence interval 1.100-13.867).</p><p><strong>Conclusions: </strong>Our findings indicate that the SARC-F score reflects sarcopenia characteristics and can predict adjuvant chemotherapy discontinuation in patients with CRC.</p>\",\"PeriodicalId\":17111,\"journal\":{\"name\":\"Journal of Surgical Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Surgical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/jso.70097\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/jso.70097","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:肌肉减少症对癌症患者的临床结果有不利影响。研究表明,在结直肠癌、食管癌、消化道癌、肝细胞癌和肾癌患者中,肌肉减少症可显著预测化疗引起的剂量限制性毒性,包括早期停药、延迟和剂量减少。力量、行走辅助、从椅子上站起来、爬楼梯和跌倒问卷(SARC-F)是一种简单有效的肌肉减少症筛查工具。辅助化疗是晚期(II/III期)结直肠癌(CRC)的标准治疗。预测化疗停止可以帮助改善肿瘤预后。本研究旨在评价SARC-F评分与停药的相关性。方法:本研究纳入了2016年7月至2023年6月接受手术治疗的139例结直肠癌患者,术前接受辅助化疗并完成SARC-F问卷调查。SARC-F包括五个项目,每个项目的得分从0到2。根据最佳SARC-F临界值将患者分为两组。采用logistic回归模型对停药情况进行分析。结果:患者分为高sarc - f组(n = 18)和低sarc - f组(n = 121)。结论:我们的研究结果表明,SARC-F评分反映了肌肉减少症的特征,可以预测结直肠癌患者的辅助化疗中断。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Preoperative Strength, Assistance in Walking, Rising From a Chair, Climbing Stairs, and Falls (SARC-F) Score Predicts Adjuvant Chemotherapy Discontinuation in Patients With Colorectal Cancer.

Background and objectives: Sarcopenia adversely affects clinical outcomes in patients with cancer. Studies indicate that sarcopenia significantly predicts chemotherapy-induced dose-limiting toxicities, including early discontinuation, delay, and dose-reduction, in patients with colorectal, esophageal, digestive, hepatocellular, and renal cancers. The Strength, Assistance for walking, Rising from a chair, Climbing stairs, and Falls (SARC-F) questionnaire is a simple and effective tool for sarcopenia screening. Adjuvant chemotherapy is the standard treatment for advanced (Stages II/III) colorectal cancer (CRC). Predicting chemotherapy discontinuation could help improve oncologic outcomes. This study aimed to evaluate the correlation between the SARC-F score and chemotherapy discontinuation.

Methods: This study included 139 patients with CRC who underwent surgery between July 2016 and June 2023, received adjuvant chemotherapy and completed the SARC-F questionnaire before surgery. The SARC-F includes five items, each scored from 0 to 2. Patients were divided into two groups based on optimal SARC-F cutoff value. Treatment discontinuation was analyzed using a logistic regression model.

Results: Patients were categorized into high-SARC-F (n = 18) and low-SARC-F (n = 121) groups. Patients in the high-SARC-F group were older (p < 0.001), had higher rates of hypertension (p = 0.001) and diabetes mellitus (p = 0.017), elevated preoperative C-reactive protein levels (p < 0.001), and a higher incidence of treatment discontinuation (p = 0.010). Univariate and multivariate analyses identified a high SARC-F score as an independent risk factor for chemotherapy discontinuation (odds ratio 3.905, 95% confidence interval 1.100-13.867).

Conclusions: Our findings indicate that the SARC-F score reflects sarcopenia characteristics and can predict adjuvant chemotherapy discontinuation in patients with CRC.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.70
自引率
4.00%
发文量
367
审稿时长
2 months
期刊介绍: The Journal of Surgical Oncology offers peer-reviewed, original papers in the field of surgical oncology and broadly related surgical sciences, including reports on experimental and laboratory studies. As an international journal, the editors encourage participation from leading surgeons around the world. The JSO is the representative journal for the World Federation of Surgical Oncology Societies. Publishing 16 issues in 2 volumes each year, the journal accepts Research Articles, in-depth Reviews of timely interest, Letters to the Editor, and invited Editorials. Guest Editors from the JSO Editorial Board oversee multiple special Seminars issues each year. These Seminars include multifaceted Reviews on a particular topic or current issue in surgical oncology, which are invited from experts in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信